Walking away from depression: the mediating role of walking activity in depression impacting blood glucose levels of people with diabetes or prediabetes.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2024
Historique:
received: 09 06 2024
accepted: 24 07 2024
medline: 11 9 2024
pubmed: 11 9 2024
entrez: 11 9 2024
Statut: epublish

Résumé

Depression can exacerbate diabetes by impairing self-care behaviors and increasing the risk of complication; however, the underlying mechanism is still unclear. Given the suggested associations between walking activity, depression status, and blood glucose levels this study explores the intricate relationship between depression and blood glucose (BG) control, with a focus on walking activity as a behavioral mediator. The purpose of this study is to examine walking activity's mediating role in depression's impact on BG levels, investigating and validating the non-linear association between BG levels and walking activity. This retrospective real-world study demonstrates the potential of regular walking activity as a simple and accessible intervention to mitigate the negative effects of depression on BG levels in T2D and prediabetes. A cohort of 989 users with T2D and prediabetes, who regularly tracked their steps levels and BG levels for 12 months using the Dario digital health platform was evaluated. The mediating role of the monthly average number of steps on the relationship between the self-reported depression status and lagged monthly average BG was assessed. Additionally, the association between monthly walking activity and monthly average BG was tested using a piecewise linear mixed effects model. Users with self-reported depression demonstrated increased BG levels compared to users without depression (B=8.00, P=.01). The association between depression and monthly average number of steps was significant (B=-.27, P<.005) and monthly average number of steps significantly predicted the following months' average BG (B=-.81, P=.001), adjusting for depression. The monthly average number of steps significantly mediated the effect of self-reported depression on the following month's average BG (M=.22, P<.005). Further sensitivity analysis demonstrated model robustness over various periods. Finally, non-linear dynamics of walking activity over time was validated using unseen data showing a decrease in monthly average BG for users with over an average of 400 steps per day (B=-1.87, P<.01). This study shows how regular walking may reduce the negative impact of depression on BG levels in people with T2D. Our findings advocate for the integration of walking activity into treatment protocols as a cost-effective, accessible intervention strategy to improve glycemic management and depressive symptoms in this population.

Identifiants

pubmed: 39257900
doi: 10.3389/fendo.2024.1446405
pmc: PMC11385005
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1446405

Informations de copyright

Copyright © 2024 Fundoiano-Hershcovitz, Breuer Asher, Kantor, Rahmon, Ritholz, Horwitz, Manejwala and Goldstein.

Déclaration de conflit d'intérêts

YF-H, IB, and OM are employees at Dario Health. MR and DH serve as Dario Health scientific advisory board members. PG has received a consulting fee to assist with analyses but otherwise has no conflict of interest. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Yifat Fundoiano-Hershcovitz (Y)

Clinical Department, Dario Health, Caesarea, Israel.

Inbar Breuer Asher (I)

Clinical Department, Dario Health, Caesarea, Israel.

Halit Kantor (H)

School of Public Health, University of Haifa, Haifa, Israel.

Sandy Rahmon (S)

School of Public Health, University of Haifa, Haifa, Israel.

Marilyn D Ritholz (MD)

Joslin Diabetes Center, Harvard Medical School, Boston, MA, United States.

David L Horwitz (DL)

Clinical Department, DLH Biomedical Consulting, Las Vegas, NV, United States.

Omar Manejwala (O)

Commercial-Medical Department, Dario Health, Caesarea, Israel.

Pavel Goldstein (P)

School of Public Health, University of Haifa, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH